Abstract
Piperlonguminine (PL), a major alkaloid isolated from Piper longum fruits, shows several biological activities including anti-tumor, anti-hyperlipidemic and anti-inflammatory effects. Although there have been studies of the biological effects of PL, the potential drug-interaction effect of PL following evaluation of inhibitory effects of cytochrome P450 (CYP) activities was not investigated. Here, to investigate the inhibitory effects of PL on the activities of CYP isoforms, CYP inhibition assays were conducted using a cocktail of probe substrates in pooled human liver microsome (HLMs) and human recombinant cDNA-expressed CYP. PL strongly inhibited CYP1A2-mediated phenacetin O-deethylation with an IC50 value of 8.8 μM, as NADPH-independent inhibition, while other CYPs were not significantly inhibited. A Lineweaver–Burk plot resulted in the inhibition mechanism of PL being divided into two different modes, reversible competitive inhibition in a low concentration range of 0–16 μM with a Ki value of 1.39 μM and uncompetitive inhibitory behavior at a high concentration range of 16–40 μM. In addition, PL only decreased CYP 1A2-catalyzed phenacetin O-deethylase activity with IC50 values of 10.0 μM in human recombinant cDNA-expressed 1A2, not 1A1. Overall, this is the first investigation of potential herb–drug interactions associated with PL conducted by identifying the competitive inhibitory effects of PL on CYP1A2 in HLMs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abd El-Aty, A.M., S.S. Shah, B.M. Kim, J.H. Choi, H.J. Cho, Y. Hee, B.J. Chang, H.C. Shin, K.B. Lee, M. Shimoda, and J.H. Shim. 2008. In vitro inhibitory potential of decursin and decursinol angelate on the catalytic activity of cytochrome P-450 1A1/2, 2D15, and 3A12 isoforms in canine hepatic microsomes. Archives of Pharmacal Research 31: 1425–1435.
Bertilsson, L., J.A. Carrillo, M.L. Dahl, A. Llerena, C. Alm, U. Bondesson, L. Lindstrom, I. de Rodriguez la Rubia, S. Ramos, and J. Benitez. 1994. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology 38: 471–473.
Bezerra, D.P., C. Pessoa, M.O. Moraes, N.M. Alencar, R.O. Mesquita, M.W. Lima, A.P. Alves, O.D. Pessoa, J.H. Chaves, E.R. Silveira, and L.V. Costa-Lotufo. 2008. In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. Journal of Applied Toxicology 28: 599–607.
Bourrie, M., V. Meunier, Y. Berger, and G. Fabre. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 277: 321–332.
Brosen, K., E. Skjelbo, B.B. Rasmussen, H.E. Poulsen, and S. Loft. 1993. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochemical Pharmacology 45: 1211–1214.
Chae, J.W., I.H. Baek, and K.I. Kwon. 2012. Effect of decursin on the pharmacokinetics of theophylline and its metabolites in rats. Journal of Ethnopharmacology 144: 248–254.
Chen, Y., Y. Tang, G.T. Robbins, D. Nie. (2010). Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. Journal of Pharmacology and Experimental Therapeutics 334: 999–1008.
Guengerich, F.P. (1997). Role of cytochrome P450 enzymes in drug-drug interactions. Advances in pharmacology 43: 7–35.
Kumar, S., J. Kamboj, Suman, and S. Sharma. 2011. Overview for various aspects of the health benefits of Piper longum linn. fruit. Journal of Acupuncture and Meridian Studies 4: 134–140.
Lee, W., H. Yoo, J.A. Kim, S. Lee, J.G. Jee, M.Y. Lee, Y.M. Lee, and J.S. Bae. 2013. Barrier protective effects of piperlonguminine in LPS-induced inflammation in vitro and in vivo. Food and Chemical Toxicology 58C: 149–157.
Liu, J., Y. Bi, R. Luo, and X. Wu. 2011. Simultaneous UFLC-ESI-MS/MS determination of piperine and piperlonguminine in rat plasma after oral administration of alkaloids from Piper longum L.: Application to pharmacokinetic studies in rats. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 879: 2885–2890.
Nebert, D.W., Z. Shi, M. Galvez-Peralta, S. Uno, and N. Dragin. 2013. Oral Benzo[a]pyrene: Understanding pharmacokinetics, detoxication and consequences—Cyp1 knockout mouse lines as a paradigm. Molecular Pharmacology 84: 304–313.
Perera, V., A.S. Gross, and A.J. McLachlan. 2012. Measurement of CYP1A2 activity: A focus on caffeine as a probe. Current Drug Metabolism 13: 667–678.
Qi, H.S., P. Liu, S.Q. Gao, Z.Y. Diao, L.L. Yang, J. Xu, X. Qu, and E.J. Han. 2009. Inhibitory effect of piperlonguminine/dihydropiperlonguminine on the production of amyloid beta and APP in SK-N-SH cells. Chinese Journal of Physiology 52: 160–168.
Rochat, B. (2005). Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clinical pharmacokinetics 44: 349–366.
Sarnaizul, E., G. Borjihan, H. Baigude, Aona, Menghe, Narisu, and Zhaorigetu. 2013. LC analysis and pharmacokinetic study of synthetic piperlonguminine in rat plasma after oral administration. Biomedical Chromatography 27: 821–824.
Shimada, T. 2006. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metabolism and Pharmacokinetics 21: 257–276.
Shoba, G., D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P.S. Srinivas. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 64: 353–356.
Strandell, J., O. Caster, J. Hopstadius, I.R. Edwards, and G.N. Noren. 2013. The development and evaluation of triage algorithms for early discovery of adverse drug interactions. Drug Safety 36: 371–388.
Wang, B., and S.F. Zhou. 2009. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Current Medicinal Chemistry 16: 4066–4218.
Yamaguchi, I., Matsuda, H., Zhang, H., Hamao, M., Yamashita, C., Kogami, Y., Kon’i, H., Murata, M., Nakamura, S., Yoshikawa, M. (2013). Adipogenic effects of piperlonguminine in 3T3-L1 cells and plasma concentrations of several amide constituents from Piper chaba extracts after treatment of mice. Journal of Natural Medicines.
Zhang, Y.H., Y.J. Zhang, Y.L. Guo, W.J. Li, and C. Yu. 2013. Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats. Journal of Pharmacy and Pharmacology 65: 149–155.
Zhuang, X.M., Y.H. Zhong, W.B. Xiao, H. Li, and C. Lu. 2013. Identification and characterization of psoralen and isopsoralen as potent CYP1A2 reversible and time-dependent inhibitors in human and rat preclinical studies. Drug Metabolism and Disposition 41: 1914–1922.
FDA documents
Guidance for Industry Drug. (2006). Interaction studies—Study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/cder//guidance.
Acknowledgments
This work was supported by the National Research Foundation (NRF) grant funded by the Korean government (MSIP) (NRF-2012R1A4A1028835).
Author information
Authors and Affiliations
Corresponding author
Additional information
Min Song and Jae Yun Hwang have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Song, M., Hwang, J.Y., Lee, M.Y. et al. In vitro inhibitory effect of piperlonguminine isolated from Piper longum on human cytochrome P450 1A2. Arch. Pharm. Res. 37, 1063–1068 (2014). https://doi.org/10.1007/s12272-013-0281-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0281-5